Moreover, several retrospective series have shown that stereotactic radiation and cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) inhibitor or PD-1 inhibitor can be combined safely for melanoma patients with brain metastases [24, 25]. The gene discussed is CTLA4; the disease is melanoma.